3 reasons Edwards Lifesciences (EW) was downgraded at Piper Sandler today
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Edwards Lifesciences (EW) cut to underperform at Bernstein as organic growth slows
January 31, 2023 12:03 PM ESTBernstein analyst Lee Hambright double downgraded Edwards Lifesciences (NYSE: EW) to Underperform from Outperform on Tuesday, cutting the firm's price target on the stock to $66 from $95 per share.
The analyst said in a research note to clients that Edwards Lifesciences is a high-quality company and a leading medtech innovator, with investors... More
Piper Sandler Downgrades Edwards Lifesciences (EW) to Neutral
January 30, 2023 3:40 AM EST(Updated - January 30, 2023 6:53 AM EST)
Piper Sandler analyst Adam Maeder downgraded Edwards Lifesciences (NYSE: EW) from Overweight to Neutral with a price target of $80.00 (from $95.00).
The analyst comments... More
